Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

Human immunodeficiency virus-infected women (n = 16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Unadkat, Jashvant D., Wara, Diane W., Hughes, Michael D., Mathias, Anita A., Holland, Diane T., Paul, Mary E., Connor, James, Huang, Sharon, Nguyen, Bach-Yen, Watts, D. Heather, Mofenson, Lynne M., Smith, Elizabeth, Deutsch, Paul, Kaiser, Kathleen A., Tuomala, Ruth E.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2007
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1797783/
https://ncbi.nlm.nih.gov/pubmed/17158945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00420-06
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares